Page 12 - Daniel Vitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immunic to Participate in Industry and Investor Conferences in September

NEW YORK, Sept. 6, 2023 /PRNewswire/ Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and.

Research triangle parkNorth carolinaUnited statesDaniel vittEdna kaplanPatrick walshPaula schwartzBiopharm americaJessica breuRx communications groupImmunic incExchange commissionChief business officerGlobal healthcareChief executive officerNew york

EQS-News: Immunic to Participate in Industry and Investor Conferences in September

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Industry and Investor Conferences in September 06.09.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Industry and Investor Conferences in September NEW.

North carolinaUnited statesResearch triangle parkPatrick walshDaniel vittEdna kaplanPaula schwartzJessica breuBiopharm americaDistribution servicesImmunic incRx communications groupExchange commissionInvestor conferencesChief business officerGlobal healthcare

Phase 2 trial of vidofludimus calcium in progressive MS fully enrolled | Study to show if potential seen with RRMS extends to PPMS, SPMS

Phase 2 trial of vidofludimus calcium in progressive MS fully enrolled | Study to show if potential seen with RRMS extends to PPMS, SPMS
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel vittAndreas muehlerImmunic therapeuticsNorth america

Immunic CEO hails great day after completing IMU-838 phase 2 trial enrolment

Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion.

Thomas warnerDaniel vittImmunic inc

EQS-News: Immunic, Inc : Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

EQS-News: Immunic, Inc : Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesEdna kaplanPaula schwartzDaniel vittAndreas muehlerJessica breuImmunic incExchange commissionRx communications groupDistribution servicesCompletes enrollmentIts phaseVidofludimus calciumProgressive multiple sclerosisProgressive multipleInterim biomarker analysis expected